|Delayed - 11/26 01:00:01 pm|
Vir Biotechnology, Inc. Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 202110/15/2021 | 08:30am
Vir Biotechnology, Inc. announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been accepted for oral and poster presentation at the American ssociation for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place virtually from November 12-15, 2021. Among the accepted abstracts is an oral presentation of new data from a Phase 2 study evaluating VIR-2218, an investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi), alone and in combination with pegylated interferon alfa-2a (PEG-IFNa), an approved immunomodulator for the treatment of chronic hepatitis B virus (HBV), for the potential functional cure of chronic HBV infection. Additionally, two poster presentations will highlight pre-clinical and clinical data for VIR-3434, an investigational HBV-neutralizing monoclonal antibody designed to inhibit HBV entry into cells, reduce the number of virion and subvirion particles in the blood, and potentially function as a therapeutic T cell vaccine. A third poster presentation will focus on the impact of chronic HBV and its treatments on patients’ lives, as well as the perceived value of a functional cure.
© S&P Capital IQ 2021
All news about VIR BIOTECHNOLOGY, INC.